Premium
Phosphorylated FADD is not prognostic for local control in T1‐T2 supraglottic laryngeal carcinoma treated with radiotherapy
Author(s) -
Wachters Jan E.,
Schrijvers Michiel L.,
SlagterMenkema Lorian,
Mastik Mirjam,
Langendijk Johannes A.,
de Bock Geertruida H.,
Roodenburg Jan L.,
van der Laan Bernard F.A.M.,
van der Wal Jacqueline E.,
Schuuring Ed
Publication year - 2017
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.26563
Subject(s) - fadd , medicine , oncology , radiation therapy , hazard ratio , carcinoma , proportional hazards model , larynx , head and neck squamous cell carcinoma , survival analysis , confidence interval , pathology , head and neck cancer , surgery , apoptosis , biology , programmed cell death , caspase , biochemistry
Objective The Fas‐Associated Death Domain (FADD) gene is located in the chromosome 11q13‐region and frequently is amplified in head and neck squamous cell carcinoma. Expression of FADD and its phosphorylated isoform (pFADD) have been associated with aggressive tumor growth, lymph node metastasis, and overall survival. Previously, we demonstrated that pFADD expression was related to a significantly improved local control in early stage (tumor [T]1 to T2) glottic laryngeal squamous cell carcinoma (LSCC). The aim of this study was to examine the prognostic value of pFADD and FADD in T1 to T2 supraglottic LSCC treated with primarily radiotherapy. Methods Tumor tissue sections of 60 patients with T1 to T2 supraglottic LSCC treated with primarily radiotherapy were assessed immunohistochemically for expression of pFADD and FADD. Expression percentages and clinical parameters and their associations with clinical outcome were studied using Cox regression and Kaplan‐Meier survival analyses. Expression percentages in supraglottic and glottic LSCC were compared using the Mann‐Whitney U test. Results Expression of pFADD and FADD in supraglottic and glottic LSCC did not significantly differ. In supraglottic LSCC, both pFADD and FADD did not show prognostic value for local control (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.98–1.03; HR 1.03, 95% CI 0.60–1.78, respectively) and overall survival (HR 0.99, 95% CI 0.98–1.01; HR 1.19, 95% CI 0.83–1.71 respectively). In this cohort, lymph node status was the best predictor for local control (HR 3.73, 95% CI 1.30–10.67). Conclusion In this homogeneous cohort of T1 to T2 supraglottic LSCC primarily treated with radiotherapy, lymph node status was associated with local recurrence, whereas the expression of pFADD was not. Level of Evidence NA. Laryngoscope , 127:E301–E307, 2017